DNA Assay May Distinguish Responses to mRCC Immunotherapy
An ultra-sensitive circulating tumor DNA assay may distinguish partial and complete response to immunotherapy for metastatic kidney cancer.
Source: cancertherapyadvisor.com
Digital Sequencing News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Digital Sequencing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Digital Sequencing Today - Breaking & Trending Today
DNA Assay May Distinguish Responses to mRCC Immunotherapy
An ultra-sensitive circulating tumor DNA assay may distinguish partial and complete response to immunotherapy for metastatic kidney cancer.
Source: renalandurologynews.com
Phoenix nonprofit TGEN signs deal to expand cancer detection via blood test
Phoenix nonprofit TGen signs deal to expand cancer detection via blood test Russ Wiles, Arizona Republic © TGen Jeffrey Trent is president and research director at TGEN in Phoenix. Phoenix medical-research nonprofit TGen has licensed a blood-biopsy method to test for cancer to a for-profit public company in an effort to expand reach of the technology. Exact Sciences Corp. of Madison, Wisconsin, acquired a worldwide exclusive license from the Translational Genomics Research Institute of Phoenix for use in oncology testing. Financial terms of the agreement weren’t announc...
Source: msn.com